Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
Alba Bergas, Adaia Albasanz‐Puig, Ana Fernández‐Cruz, Marina Machado, Andrés Novo, David van Duin, Carolina García‐Vidal, Morgan Hakki, Isabel Ruíz-Camps, José Luís del Pozo, Chiara Oltolini, Catherine DeVoe, Ľuboš Drgoňa, Oriol Gasch, Małgorzata Mikulska, Pilar Martín‐Dávila, Maddalena Peghin, Lourdes Vázquez, Júlia Laporte-Amargós, Xavier Durà-Miralles, Natàlia Pallarés, Eva González‐Barca, Ana Álvarez‐Uría, Pedro Puerta‐Alcalde, Francisco Carmona-Torre, Teresa Daniela Clerici, Sarah B. Doernberg, Lucia Petríková, Sílvia Capilla, Laura Magnasco, Jesús Fortün, Nadia Castaldo, Jordi Carratalà, Carlota Gudiol
Abstract
Ceftolozane-tazobactam (C/T) has been shown to be a safe and effective alternative for the treatment of difficult to treat infections due to Pseudomonas aeruginosa (PA) in the general nonimmunocompromised population. However, the experience of this agent in immunosuppressed neutropenic patients is very limited. Our study is unique because it is focused on extremely immunosuppressed hematological patients with neutropenia and bloodstream infection (BSI) due to PA (mainly multidrug resistant [MDR]), a scenario which is often associated with very high mortality rates. In our study, we found that the use of C/T for the treatment of MDR PA BSI in hematological neutropenic patients was significantly associated with improved outcomes, and, in addition, it was found to be an independent risk factor associated with increased survival. To date, this is the largest series involving neutropenic hematologic patients with PA BSI treated with C/T.